Larson Financial Group’s Nurix Therapeutics NRIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$10.9K Buy
458
+17
+4% +$424 ﹤0.01% 2465
2026
Q2
$10.7K Sell
441
-4
-0.9% -$68 ﹤0.01% 2363
2026
Q1
$6.9K Sell
445
-1,096
-71% -$18.2K ﹤0.01% 2440
2025
Q4
$29.2K Buy
1,541
+1,190
+339% +$17.1K ﹤0.01% 1498
2025
Q3
$3.24K Buy
+351
New +$3.64K ﹤0.01% 2516
2024
Q4
– Sell
-24
Closed -$539 – 2860
2024
Q3
$539 Buy
+24
New +$544 ﹤0.01% 2106

Other funds holding NRIX

Larson Financial Group's NRIX Position: Q3 2026 in Review

Larson Financial Group increased its Nurix Therapeutics (NRIX) stake by 3.9% in Q3 2026, buying an estimated $424 and bringing the position to 458 shares worth $10.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2465.

Larson Financial Group first reported a position in NRIX in Q3 2024 and has held it in 6 quarters since. The position peaked at $29.2K in Q4 2025. 234 funds tracked by Wall St. Rank hold NRIX as of Q3 2026.

  • Larson Financial Group held 458 shares of Nurix Therapeutics worth $10.9K as of Q3 2026.
  • Larson Financial Group bought 17 Nurix Therapeutics shares in Q3 2026, an estimated $424.
  • Nurix Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q3 2026, its #2465 holding.
  • Larson Financial Group first reported a position in Nurix Therapeutics in Q3 2024 and has held it in 6 quarters since.
  • Larson Financial Group's Nurix Therapeutics position peaked at $29.2K in Q4 2025.
  • 234 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2026.

Based on Larson Financial Group's 13F filing for Q3 2026, filed 5 Nov 2026.